Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.

Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H.

Cell Rep. 2018 Apr 3;23(1):213-226.e3. doi: 10.1016/j.celrep.2018.03.047.

2.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

3.

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition.

Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN.

Cancer Res. 2018 Feb 1;78(3):781-797. doi: 10.1158/0008-5472.CAN-17-2802. Epub 2017 Dec 11.

PMID:
29229598
4.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA.

Cancer Res. 2017 Jul 15;77(14):3870-3884. doi: 10.1158/0008-5472.CAN-16-3409. Epub 2017 May 10.

5.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

6.

Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.

Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, Mani SA.

Oncogene. 2016 Nov 17;35(46):5977-5988. doi: 10.1038/onc.2016.203. Epub 2016 Jun 13.

7.

p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.

Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H.

Breast Cancer Res. 2016 Jan 27;18(1):13. doi: 10.1186/s13058-016-0673-9.

8.

Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival.

Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, Kuzmicki C, Pless R, Stappenbeck TS, Piwnica-Worms D, Piwnica-Worms H.

Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):E7148-54. doi: 10.1073/pnas.1509249112. Epub 2015 Dec 7.

9.

Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities.

Cheruiyot A, Paudyal SC, Kim IK, Sparks M, Ellenberger T, Piwnica-Worms H, You Z.

DNA Repair (Amst). 2015 Nov;35:106-15. doi: 10.1016/j.dnarep.2015.09.021. Epub 2015 Sep 30.

10.

Flap Endonuclease 1 Limits Telomere Fragility on the Leading Strand.

Teasley DC, Parajuli S, Nguyen M, Moore HR, Alspach E, Lock YJ, Honaker Y, Saharia A, Piwnica-Worms H, Stewart SA.

J Biol Chem. 2015 Jun 12;290(24):15133-45. doi: 10.1074/jbc.M115.647388. Epub 2015 Apr 28.

11.

14-3-3 proteins restrain the Exo1 nuclease to prevent overresection.

Chen X, Kim IK, Honaker Y, Paudyal SC, Koh WK, Sparks M, Li S, Piwnica-Worms H, Ellenberger T, You Z.

J Biol Chem. 2015 May 8;290(19):12300-12. doi: 10.1074/jbc.M115.644005. Epub 2015 Apr 1.

12.

Subcellular localization and Ser-137 phosphorylation regulate tumor-suppressive activity of profilin-1.

Diamond MI, Cai S, Boudreau A, Carey CJ Jr, Lyle N, Pappu RV, Swamidass SJ, Bissell M, Piwnica-Worms H, Shao J.

J Biol Chem. 2015 Apr 3;290(14):9075-86. doi: 10.1074/jbc.M114.619874. Epub 2015 Feb 13.

13.

Type I interferons link viral infection to enhanced epithelial turnover and repair.

Sun L, Miyoshi H, Origanti S, Nice TJ, Barger AC, Manieri NA, Fogel LA, French AR, Piwnica-Worms D, Piwnica-Worms H, Virgin HW, Lenschow DJ, Stappenbeck TS.

Cell Host Microbe. 2015 Jan 14;17(1):85-97. doi: 10.1016/j.chom.2014.11.004. Epub 2014 Dec 4.

14.

Contribution of p53 to metastasis.

Powell E, Piwnica-Worms D, Piwnica-Worms H.

Cancer Discov. 2014 Apr;4(4):405-14. doi: 10.1158/2159-8290.CD-13-0136. Epub 2014 Mar 21. Review.

15.

Phosphorylation of the E3 ubiquitin ligase RNF41 by the kinase Par-1b is required for epithelial cell polarity.

Lewandowski KT, Piwnica-Worms H.

J Cell Sci. 2014 Jan 15;127(Pt 2):315-27. doi: 10.1242/jcs.129148. Epub 2013 Nov 20.

16.

Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice.

Tinkum KL, White LS, Marpegan L, Herzog E, Piwnica-Worms D, Piwnica-Worms H.

J Biol Chem. 2013 Sep 27;288(39):27999-8008. doi: 10.1074/jbc.M113.494328. Epub 2013 Aug 5.

17.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM.

Breast Cancer Res Treat. 2013 Jan;137(2):483-92. doi: 10.1007/s10549-012-2378-9. Epub 2012 Dec 15.

18.

CRL4(CDT2) targets CHK1 for PCNA-independent destruction.

Huh J, Piwnica-Worms H.

Mol Cell Biol. 2013 Jan;33(2):213-26. doi: 10.1128/MCB.00847-12. Epub 2012 Oct 29.

19.

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER.

Nature. 2012 Jun 10;486(7403):353-60. doi: 10.1038/nature11143.

20.

Okazaki fragment processing-independent role for human Dna2 enzyme during DNA replication.

Duxin JP, Moore HR, Sidorova J, Karanja K, Honaker Y, Dao B, Piwnica-Worms H, Campbell JL, Monnat RJ Jr, Stewart SA.

J Biol Chem. 2012 Jun 22;287(26):21980-91. doi: 10.1074/jbc.M112.359018. Epub 2012 May 7.

21.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H.

J Clin Invest. 2012 Apr;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.

22.

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells.

Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H.

Oncogene. 2013 Jan 31;32(5):577-88. doi: 10.1038/onc.2012.84. Epub 2012 Mar 19.

23.

Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells.

Tinkum KL, Marpegan L, White LS, Sun J, Herzog ED, Piwnica-Worms D, Piwnica-Worms H.

Mol Cell Biol. 2011 Sep;31(18):3759-72. doi: 10.1128/MCB.05243-11. Epub 2011 Jul 26.

24.

Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.

Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM.

Genes Dev. 2011 Jul 1;25(13):1426-38. doi: 10.1101/gad.2024411.

25.

Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cells.

Lee G, Origanti S, White LS, Sun J, Stappenbeck TS, Piwnica-Worms H.

PLoS One. 2011 Jan 25;6(1):e15561. doi: 10.1371/journal.pone.0015561.

26.

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Ma CX, Janetka JW, Piwnica-Worms H.

Trends Mol Med. 2011 Feb;17(2):88-96. doi: 10.1016/j.molmed.2010.10.009. Epub 2010 Nov 17. Review.

PMID:
21087899
27.

Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis.

Lennerz JK, Hurov JB, White LS, Lewandowski KT, Prior JL, Planer GJ, Gereau RW 4th, Piwnica-Worms D, Schmidt RE, Piwnica-Worms H.

Mol Cell Biol. 2010 Nov;30(21):5043-56. doi: 10.1128/MCB.01472-09. Epub 2010 Aug 23.

28.

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8.

29.

Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.

Honaker Y, Piwnica-Worms H.

Oncogene. 2010 Jun 10;29(23):3324-34. doi: 10.1038/onc.2010.96. Epub 2010 Mar 29.

30.

Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis.

Qian Z, Leung-Pineda V, Xuan B, Piwnica-Worms H, Yu D.

PLoS Pathog. 2010 Mar 19;6(3):e1000814. doi: 10.1371/journal.ppat.1000814.

31.

LKB1 regulates pancreatic beta cell size, polarity, and function.

Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E, Miki T, Lennerz JK, Stoeckert CJ Jr, Meyuhas O, Seino S, Permutt MA, Piwnica-Worms H, Bardeesy N, Dor Y.

Cell Metab. 2009 Oct;10(4):296-308. doi: 10.1016/j.cmet.2009.08.010.

32.

The polarity protein Par1b/EMK/MARK2 regulates T cell receptor-induced microtubule-organizing center polarization.

Lin J, Hou KK, Piwnica-Worms H, Shaw AS.

J Immunol. 2009 Jul 15;183(2):1215-21. doi: 10.4049/jimmunol.0803887. Epub 2009 Jun 24.

33.

DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress.

Leung-Pineda V, Huh J, Piwnica-Worms H.

Cancer Res. 2009 Mar 15;69(6):2630-7. doi: 10.1158/0008-5472.CAN-08-3382. Epub 2009 Mar 10.

34.

Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion.

Lee G, White LS, Hurov KE, Stappenbeck TS, Piwnica-Worms H.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4701-6. doi: 10.1073/pnas.0900751106. Epub 2009 Mar 9.

35.

Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association.

Watkins JL, Lewandowski KT, Meek SE, Storz P, Toker A, Piwnica-Worms H.

Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18378-83. doi: 10.1073/pnas.0809661105. Epub 2008 Nov 14.

36.

Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379.

Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H.

Mol Cell Biol. 2008 Oct;28(19):5874-85. doi: 10.1128/MCB.00821-08. Epub 2008 Jul 21.

37.

Overview of the baculovirus expression system.

Murphy CI, Piwnica-Worms H.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.4. doi: 10.1002/0471140864.ps0504s00.

PMID:
18429185
38.

Overview of the baculovirus expression system.

Murphy CI, Piwnica-Worms H.

Curr Protoc Neurosci. 2001 May;Chapter 4:Unit 4.18. doi: 10.1002/0471142301.ns0418s10. Review.

PMID:
18428479
39.

Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit.

Nakajima H, Yonemura S, Murata M, Nakamura N, Piwnica-Worms H, Nishida E.

J Cell Biol. 2008 Apr 7;181(1):89-103. doi: 10.1083/jcb.200708176. Epub 2008 Mar 31.

40.

Overview of the baculovirus expression system.

Murphy CI, Piwnica-Worms H, Grünwald S, Romanow WG, Francis N, Fan HY.

Curr Protoc Mol Biol. 2004 Feb;Chapter 16:Unit 16.9. doi: 10.1002/0471142727.mb1609s65.

PMID:
18265342
41.

Expression and purification of recombinant proteins using the baculovirus system.

Murphy CI, Piwnica-Worms H, Grünwald S, Romanow WG, Francis N, Fan HY.

Curr Protoc Mol Biol. 2004 Feb;Chapter 16:Unit 16.11. doi: 10.1002/0471142727.mb1611s65.

PMID:
18265341
42.

Maintenance of insect cell cultures and generation of recombinant baculoviruses.

Murphy CI, Piwnica-Worms H, Grünwald S, Romanow WG, Francis N, Fan HY.

Curr Protoc Mol Biol. 2004 Feb;Chapter 16:Unit 16.10. doi: 10.1002/0471142727.mb1610s65.

PMID:
18265340
43.

GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H.

Cancer Cell. 2008 Jan;13(1):36-47. doi: 10.1016/j.ccr.2007.12.002.

44.

Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication.

Tarakanova VL, Leung-Pineda V, Hwang S, Yang CW, Matatall K, Basson M, Sun R, Piwnica-Worms H, Sleckman BP, Virgin HW 4th.

Cell Host Microbe. 2007 Jun 14;1(4):275-86.

46.

The Par-1/MARK family of protein kinases: from polarity to metabolism.

Hurov J, Piwnica-Worms H.

Cell Cycle. 2007 Aug 15;6(16):1966-9. Epub 2007 Jun 8. Review.

PMID:
17721078
47.

Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo.

Hurov JB, Huang M, White LS, Lennerz J, Choi CS, Cho YR, Kim HJ, Prior JL, Piwnica-Worms D, Cantley LC, Kim JK, Shulman GI, Piwnica-Worms H.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5680-5. Epub 2007 Mar 19.

48.

Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit.

Leung-Pineda V, Ryan CE, Piwnica-Worms H.

Mol Cell Biol. 2006 Oct;26(20):7529-38. Epub 2006 Aug 5.

49.

New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases.

Dequiedt F, Martin M, Von Blume J, Vertommen D, Lecomte E, Mari N, Heinen MF, Bachmann M, Twizere JC, Huang MC, Rider MH, Piwnica-Worms H, Seufferlein T, Kettmann R.

Mol Cell Biol. 2006 Oct;26(19):7086-102.

50.

Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity.

Chen YM, Wang QJ, Hu HS, Yu PC, Zhu J, Drewes G, Piwnica-Worms H, Luo ZG.

Proc Natl Acad Sci U S A. 2006 May 30;103(22):8534-9. Epub 2006 May 22.

Supplemental Content

Loading ...
Support Center